Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Fierce Pharma
Editor's Corner—Summit must submit to Big Pharma, stat
The debatable HARMONi data, along with the trial design flaws and a rapidly evolving competitive landscape, suggest a need for Summit to partner up.
Angus Liu
Sep 10, 2025 2:50pm
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
Sep 8, 2025 11:00am
Fierce Pharma
Roche touts Tecentriq biomarker win in bladder cancer
Aug 18, 2025 4:17pm
Pfizer CEO makes case for $6B bet on 'fabulous' bispecific
Jun 10, 2025 9:56am
Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in
Jun 4, 2025 1:00pm
BMS inks $11B biobucks BioNTech deal to join bispecific rush
Jun 2, 2025 8:59am